

Ben Davidson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8776070/ben-davidson-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

252
papers

8,517
citations

52
h-index

78
g-index

262
ext. papers

9,561
ext. citations

4.8
avg, IF

5.99
L-index

#	Paper	IF	Citations
252	Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. <i>Cancer</i> , 2005 , 103, 1631-43	6.4	319
251	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 18708-13	11.5	311
250	MicroRNA expression and identification of putative miRNA targets in ovarian cancer. <i>PLoS ONE</i> , 2008 , 3, e2436	3.7	273
249	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1051-66	12	178
248	The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. <i>American Journal of Surgical Pathology</i> , 2001 , 25, 1405-12	6.7	155
247	Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. <i>American Journal of Pathology</i> , 2010 , 177, 1087-94	5.8	137
246	High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 1999 , 17, 799-808	4.7	130
245	NK- and B-Cell Infiltration Correlates With Worse Outcome in Metastatic Ovarian Carcinoma. <i>American Journal of Clinical Pathology</i> , 2006 , 125, 451-458	1.9	122
244	Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. <i>Cancer Research</i> , 2004 , 64, 3572-9	10.1	113
243	Epithelial-mesenchymal transition in ovarian carcinoma. <i>Frontiers in Oncology</i> , 2012 , 2, 33	5.3	111
242	EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 161-9	4.7	111
241	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , 2015 , 7, 108	14.4	110
240	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015 , 28, 1101-22	9.8	107
239	Exosome-derived miRNAs and ovarian carcinoma progression. <i>Carcinogenesis</i> , 2014 , 35, 2113-20	4.6	104
238	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 18739-44	11.5	104
237	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. <i>Cancer Cell</i> , 2015 , 28, 82-96	24.3	96
236	miRNA profiling along tumour progression in ovarian carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 1593-602	5.6	96

235	Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. <i>Cancer Research</i> , 2005 , 65, 331-7	10.1	94
234	E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. <i>Journal of Pathology</i> , 2000 , 192, 460-9	9.4	93
233	Expression of E-cadherin transcriptional regulators in ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 520-8	5.1	92
232	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. <i>Clinical Cancer Research</i> , 2006 , 12, 5944-50	12.9	89
231	Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. <i>Human Pathology</i> , 2008 , 39, 87-95	3.7	87
230	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. <i>Modern Pathology</i> , 2018 , 31, 674-684	9.8	84
229	Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. <i>Cancer</i> , 2004 , 100, 2139-47	6.4	83
228	HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2005 , 96, 42-7	4.9	83
227	Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma. <i>PLoS ONE</i> , 2012 , 7, e39354	3.7	83
226	Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 610-8	5	81
225	Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. <i>BMC Cancer</i> , 2014 , 14, 80	4.8	80
224	Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. <i>Clinical Cancer Research</i> , 2003 , 9, 2248-59	12.9	76
223	Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006 , 449, 31-9	5.1	73
222	Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 119-28	4.4	73
221	The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. <i>Gynecologic Oncology</i> , 2006 , 102, 453-61	4.9	69
220	Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation. <i>Cell Reports</i> , 2014 , 7, 501-513	10.6	68
219	MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma. <i>Cancer Letters</i> , 2014 , 347, 75-8	9.9	68
218	Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. <i>Clinical Cancer Research</i> , 2006 , 12, 791-9	12.9	68

217	Malignant effusions: from diagnosis to biology. <i>Diagnostic Cytopathology</i> , 2004 , 31, 246-54	1.4	68
216	AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. <i>Gynecologic Oncology</i> , 2003 , 90, 248-57	4.9	68
215	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1534-1542	3.5	62
214	Ovarian cancer: diagnostic, biological and prognostic aspects. <i>Women's Health</i> , 2014 , 10, 519-33	3	62
213	Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. <i>PLoS ONE</i> , 2010 , 5, e11198	3.7	62
212	Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. <i>Human Pathology</i> , 2012 , 43, 2062-9	3.7	61
211	Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. <i>Human Pathology</i> , 2008 , 39, 747-57	3.7	61
210	Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. <i>Clinical Cancer Research</i> , 2004 , 10, 7335-46	12.9	60
209	Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. <i>Human Pathology</i> , 2009 , 40, 1453-60	3.7	59
208	Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. <i>Cancer</i> , 2007 , 109, 228-38	6.4	58
207	Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 621-31	4.7	57
206	Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. <i>Clinical and Experimental Metastasis</i> , 2010 , 27, 161-72	4.7	56
205	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. <i>Human Pathology</i> , 2014 , 45, 691-700	3.7	55
204	Tenascin-X is a novel diagnostic marker of malignant mesothelioma. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1673-82	6.7	54
203	Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. <i>Human Pathology</i> , 2007 , 38, 986-994	3.7	53
202	Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. <i>Gynecologic Oncology</i> , 2003 , 91, 160-72	4.9	53
201	Infertility treatment after conservative management of borderline ovarian tumors. <i>Cancer</i> , 2001 , 92, 320-5	6.4	53
200	MicroRNAs in Ovarian Cancer. <i>Human Pathology</i> , 2015 , 46, 1245-56	3.7	51

199	Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. <i>Human Pathology</i> , 2009 , 40, 795-806	3.7	48
198	Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. <i>American Journal of Clinical Pathology</i> , 2002 , 118, 85-92	1.9	46
197	Pathogenesis of ovarian cancer: clues from selected overexpressed genes. <i>Future Oncology</i> , 2009 , 5, 1641-57	3.6	45
196	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. <i>Cancer Research</i> , 2016 , 76, 6351-6361	10.1	45
195	Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. <i>Journal of Oncology</i> , 2010 , 2010, 285191	4.5	44
194	Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?. <i>Cancer and Metastasis Reviews</i> , 2003 , 22, 103-15	9.6	44
193	The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. <i>Human Pathology</i> , 2015 , 46, 1-8	3.7	42
192	D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 878-82	6.7	42
191	Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. <i>Clinics in Laboratory Medicine</i> , 2003 , 23, 729-54, viii	2.1	42
190	Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. <i>Gynecologic Oncology</i> , 2014 , 135, 118-24	4.9	41
189	Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 3197-206	12.9	41
188	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 535-44	5.6	41
187	Class III β tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. <i>Human Pathology</i> , 2011 , 42, 1019-26	3.7	40
186	Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. <i>Human Pathology</i> , 2010 , 41, 794-804	3.7	40
185	MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. <i>Diagnostic Cytopathology</i> , 2007 , 35, 756-60	1.4	39
184	Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. <i>Gynecologic Oncology</i> , 2006 , 103, 814-9	4.9	39
183	Cytogenetic and molecular profile of endometrial stromal sarcoma. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 834-46	5	39
182	Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. <i>Cancer</i> , 2007 , 110, 1264-71	6.4	38

181	Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. <i>Lung Cancer</i> , 2004 , 44, 159-65	5.9	38
180	The clinical and diagnostic role of microRNAs in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014 , 133, 640-6	4.9	37
179	The diagnostic role of claudins in serous effusions. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 928-37	1.9	37
178	Biological characteristics of cancers involving the serosal cavities. <i>Critical Reviews in Oncogenesis</i> , 2007 , 13, 189-227	1.3	37
177	Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. <i>Cancer Research</i> , 2008 , 68, 9265-73	10.1	36
176	Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. <i>Gynecologic Oncology</i> , 2007 , 104, 311-9	4.9	36
175	Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. <i>Cancer</i> , 2008 , 112, 84-93	6.4	36
174	Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. <i>American Journal of Surgical Pathology</i> , 2001 , 25, 1493-500	6.7	36
173	PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2003 , 9, 1412-9	12.9	36
172	Prognostic biomarkers in endometrial and ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 315-31	5.1	35
171	Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. <i>Gynecologic Oncology</i> , 2013 , 128, 349-55	4.9	34
170	Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma. <i>International Journal of Gynecological Pathology</i> , 2009 , 28, 211-21	3.2	34
169	Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. <i>Clinical and Experimental Metastasis</i> , 2002 , 19, 135-44	4.7	34
168	Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications. <i>Clinical and Experimental Metastasis</i> , 2000 , 18, 197-202	4.7	33
167	The role of the tumor stroma in ovarian cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 104	5.3	32
166	Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters. <i>American Journal of Clinical Pathology</i> , 2009 , 132, 756-62	1.9	32
165	Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. <i>CytoJournal</i> , 2015 , 12, 26	1.1	32
164	Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. <i>Clinical and Experimental Metastasis</i> , 2004 , 21, 469-76	4.7	31

163	Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. <i>Analytical Cellular Pathology</i> , 2001 , 23, 107-28		31
162	BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6585-92	12.9	30
161	CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. <i>Molecular Cancer</i> , 2015 , 14, 44	42.1	28
160	Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. <i>Molecular Pharmaceutics</i> , 2011 , 8, 2080-8	5.6	28
159	Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. <i>Acta Cytologica</i> , 2006 , 50, 603-7	3	28
158	Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. <i>Cancer</i> , 2005 , 103, 2313-9	6.4	28
157	Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells sensitivity to paclitaxel. <i>Oncotarget</i> , 2016 , 7, 12267-85	3.3	28
156	The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006 , 103, 831-40	4.9	27
155	Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. <i>Human Pathology</i> , 2007 , 38, 1030-1036	3.7	27
154	Recently identified drug resistance biomarkers in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 569-78	3.8	26
153	Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?. <i>European Journal of Cancer</i> , 2012 , 48, 2146-54	7.5	26
152	Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. <i>Diagnostic Cytopathology</i> , 2015 , 43, 512-74	1.4	25
151	Caveolin-1 expression in ovarian carcinoma is MDR1 independent. <i>American Journal of Clinical Pathology</i> , 2002 , 117, 225-34	1.9	25
150	Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection. <i>Molecular Oncology</i> , 2015 , 9, 1129-39	7.9	24
149	Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. <i>Human Pathology</i> , 2013 , 44, 2677-83	3.7	24
148	Genomewide copy number analysis of Müllerian adenocarcinoma identified chromosomal instability in the aggressive subgroup. <i>Modern Pathology</i> , 2016 , 29, 1070-82	9.8	23
147	Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. <i>Human Pathology</i> , 2012 , 43, 496-505	3.7	23
146	Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. <i>Human Pathology</i> , 2012 , 43, 684-94	3.7	23

145	HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 460, 505-13	5.1	23
144	Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls. <i>Cytometry Part B - Clinical Cytometry</i> , 2007 , 72, 332-43	3.4	23
143	The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. <i>Clinical and Experimental Metastasis</i> , 2004 , 21, 191-9	4.7	23
142	APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 51-7	1.9	22
141	SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. <i>Human Pathology</i> , 2012 , 43, 669-74	3.7	22
140	Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. <i>Nature Protocols</i> , 2008 , 3, 955-64	18.8	22
139	Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. <i>Molecular Cancer</i> , 2005 , 4, 26	42.1	22
138	Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 15, 535-44	5.6	22
137	Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2015 , 139, 30-9	4.9	21
136	Prognostic factors in malignant pleural mesothelioma. <i>Human Pathology</i> , 2015 , 46, 789-804	3.7	21
135	Angiogenic molecule expression is downregulated in effusions from breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2005 , 94, 71-80	4.4	21
134	Identification of an fusion transcript in low-grade endometrial stromal sarcoma. <i>Oncotarget</i> , 2018 , 9, 19203-19208	3.3	21
133	HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. <i>Gynecologic Oncology</i> , 2013 , 129, 358-63	4.9	20
132	Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. <i>Human Pathology</i> , 2010 , 41, 1109-19	3.7	20
131	CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival. <i>Breast</i> , 2010 , 19, 493-8	3.6	20
130	Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2003 , 20, 599-609	4.7	20
129	Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. <i>Diagnostic Cytopathology</i> , 2005 , 33, 325-31	1.4	20
128	Kallikrein 4 Expression Is Up-Regulated in Epithelial Ovarian Carcinoma Cells in Effusions. <i>American Journal of Clinical Pathology</i> , 2005 , 123, 360-368	1.9	20

127	Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry. <i>Diagnostic Cytopathology</i> , 2001 , 25, 214-9	1.4	20
126	L1CAM as a prognostic marker in stage I endometrial cancer: a validation study. <i>BMC Cancer</i> , 2016 , 16, 596	4.8	20
125	The biological role and regulation of matrix metalloproteinases (MMP) in cancer. <i>Arkhiv Patologii</i> , 2002 , 64, 47-53	0.2	20
124	SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019 , 153, 651-660	4.9	19
123	CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. <i>Human Pathology</i> , 2016 , 58, 123-127	3.7	19
122	BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 464, 701-7	5.1	19
121	Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. <i>Tumor Biology</i> , 2009 , 30, 15-25	2.9	19
120	Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009 , 454, 71-9	5.1	19
119	Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. <i>Human Pathology</i> , 2009 , 40, 527-37	3.7	19
118	The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. <i>Gynecologic Oncology</i> , 2006 , 100, 462-8	4.9	19
117	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , 2020 , 80, 4514-4526	10.1	19
116	Pre-analytical issues in effusion cytology. <i>Pleura and Peritoneum</i> , 2016 , 1, 45-56	2	19
115	Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. <i>Gynecologic Oncology</i> , 2016 , 140, 512-7	4.9	18
114	Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. <i>Human Pathology</i> , 2012 , 43, 529-35	3.7	18
113	Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. <i>Human Pathology</i> , 2009 , 40, 705-13	3.7	18
112	Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications. <i>Diagnostic Cytopathology</i> , 2007 , 35, 568-78	1.4	18
111	New determinates of disease progression and outcome in metastatic ovarian carcinoma. <i>Histology and Histopathology</i> , 2010 , 25, 1591-609	1.4	18
110	Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 449-58	1.9	18

109	Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1916-1922	3.1	17
108	Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. <i>Cancer</i> , 2012 , 118, 1543-53	6.4	17
107	MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. <i>Gynecologic Oncology</i> , 2012 , 126, 460-5	4.9	17
106	New diagnostic and molecular characteristics of malignant mesothelioma. <i>Ultrastructural Pathology</i> , 2008 , 32, 227-40	1.3	17
105	Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma. <i>Current Cancer Drug Targets</i> , 2007 , 7, 109-20	2.8	17
104	Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2018 , 148, 559-566	4.9	16
103	Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. <i>Human Pathology</i> , 2013 , 44, 777-85	3.7	16
102	Breast carcinoma cells in primary tumors and effusions have different gene array profiles. <i>Journal of Oncology</i> , 2010 , 2010, 969084	4.5	16
101	Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review. <i>Diagnostic Cytopathology</i> , 2009 , 37, 613-24	1.4	16
100	Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 1133-45	6.3	16
99	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018 , 168, 326-334	8	15
98	Nucleoside transporters are widely expressed in ovarian carcinoma effusions. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 467-75	3.5	15
97	Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. <i>Tumor Biology</i> , 2011 , 32, 589-96	2.9	15
96	Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. <i>American Journal of Clinical Pathology</i> , 2007 , 127, 752-9	1.9	15
95	Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. <i>American Journal of Clinical Pathology</i> , 2007 , 128, 389-97	1.9	15
94	RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13). <i>Genes Chromosomes and Cancer</i> , 2018 , 57, 176-181	5	15
93	VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival. <i>Human Pathology</i> , 2014 , 45, 1520-8	3.7	14
92	Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. <i>Human Pathology</i> , 2013 , 44, 1859-66	3.7	14

91	Ezrin Is Associated with Disease Progression in Ovarian Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0162502	3.7	14
90	The diagnostic role of BAP1 in serous effusions. <i>Human Pathology</i> , 2018 , 79, 122-126	3.7	14
89	Molecular characteristics of uterine sarcomas. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 515-522	3.8	13
88	Involvement of DPP9 in gene fusions in serous ovarian carcinoma. <i>BMC Cancer</i> , 2017 , 17, 642	4.8	13
87	The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. <i>Scientific Reports</i> , 2018 , 8, 11069	4.9	13
86	HMGA2 expression pattern and TERT mutations in tumors of the vulva. <i>Oncology Reports</i> , 2015 , 33, 2675-2680	3.8	13
85	Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13). <i>Cancer Letters</i> , 2015 , 357, 502-9	9.9	13
84	Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 527-40	4.7	13
83	Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. <i>Diagnostic Cytopathology</i> , 2011 , 39, 562-6	1.4	13
82	The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome. <i>PLoS ONE</i> , 2009 , 4, e5136	3.7	13
81	Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. <i>American Journal of Obstetrics and Gynecology</i> , 2008 , 199, 533.e1-8	6.4	13
80	Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva. <i>Oncotarget</i> , 2016 , 7, 85058-85062	3.3	13
79	MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. <i>Human Pathology</i> , 2016 , 47, 104-8	3.7	13
78	Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0140168	3.7	12
77	Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 103-17	4.7	12
76	Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. <i>Human Pathology</i> , 2008 , 39, 1630-6	3.7	12
75	The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. <i>Seminars in Diagnostic Pathology</i> , 2006 , 23, 35-43	4.3	12
74	ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 134-138	3.6	12

73	CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. <i>EBioMedicine</i> , 2020 , 56, 102783	8.8	11
72	HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. <i>Human Pathology</i> , 2016 , 48, 95-101	3.7	11
71	Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012 , 91, 308-17	3.8	11
70	Low frequency of ESRR-A-C11orf20 fusion gene in ovarian carcinomas. <i>PLoS Biology</i> , 2014 , 12, e1001784	9.7	11
69	Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012 , 460, 193-202	5.1	11
68	Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression. <i>Oncotarget</i> , 2017 , 8, 21554-21560	3.3	11
67	REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker. <i>PLoS ONE</i> , 2016 , 11, e0151590	3.7	11
66	Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes. <i>Clinical Cancer Research</i> , 2019 , 25, 2155-2165	12.9	11
65	Biomarkers of drug resistance in ovarian cancer - an update. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 469-476	3.8	10
64	Malignant Nonhematological Effusion Characterization by Flow Cytometry. <i>Acta Cytologica</i> , 2016 , 60, 365-371	3	10
63	Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. <i>Human Pathology</i> , 2013 , 44, 2449-60	3.7	10
62	Intra-Genome DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers. <i>PLoS ONE</i> , 2015 , 10, e0143178	3.7	10
61	Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. <i>Human Pathology</i> , 2011 , 42, 991-7	3.7	10
60	BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. <i>Human Pathology</i> , 2016 , 54, 64-73	3.7	10
59	PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. <i>American Journal of Clinical Pathology</i> , 2012 , 137, 240-7	1.9	9
58	Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. <i>Scientific Reports</i> , 2019 , 9, 18555	4.9	9
57	Reproducibility of measurement of myometrial invasion in endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 63-68	5.1	8
56	TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. <i>Human Pathology</i> , 2017 , 60, 180-187	3.7	8

55	The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions. <i>Breast Journal</i> , 2008 , 14, 476-82	1.2	8
54	MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. <i>Human Pathology</i> , 2016 , 54, 74-81	3.7	8
53	MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 61800-61809	3.3	7
52	A novel truncated form of in tumors of the ovaries. <i>Oncology Letters</i> , 2016 , 12, 1559-1563	2.6	7
51	Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways. <i>Journal of Oncology</i> , 2019 , 2019, 7547469	4.5	7
50	AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 462, 163-73	5.1	7
49	Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors. <i>Diagnostic Cytopathology</i> , 2008 , 36, 637-44	1.4	7
48	Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 177-185	5.1	7
47	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , 2019 , 47, 184-194	8.8	6
46	Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors. <i>Apmis</i> , 2017 , 125, 781-786	3.8	5
45	Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. <i>Journal of Physical Education and Sports Management</i> , 2019 , 5,	2.8	5
44	Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 473, 463-470	5.1	5
43	Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 355-362	5.1	5
42	The diagnostic and research applications of flow cytometry in cytopathology. <i>Diagnostic Cytopathology</i> , 2012 , 40, 525-35	1.4	5
41	Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 249-258	5.1	5
40	Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
39	The diagnostic role of PTEN and ARID1A in serous effusions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 472, 425-432	5.1	5
38	Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. <i>Human Pathology</i> , 2017 , 62, 115-121	3.7	4

37	Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas. <i>International Journal of Cancer</i> , 2018 , 143, 1379-1387	7.5	4
36	Migfilin, Eparvin and Eparvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. <i>Gynecologic Oncology</i> , 2013 , 128, 364-70	4.9	4
35	Molecular characterization of carcinosarcomas arising in the uterus and ovaries. <i>Oncotarget</i> , 2019 , 10, 3614-3624	3.3	4
34	Soluble AXL is ubiquitously present in malignant serous effusions. <i>Gynecologic Oncology</i> , 2019 , 152, 408-415	4.5	4
33	Repurposing F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. <i>Theranostics</i> , 2021 , 11, 6044-6057	12.1	4
32	Bilateral ovarian carcinomas differ in the expression of metastasis-related genes. <i>Oncology Letters</i> , 2017 , 13, 184-190	2.6	3
31	Hepatocyte nuclear factor-1 α s not a specific marker of clear cell carcinoma in serous effusions. <i>Cancer Cytopathology</i> , 2014 , 122, 153-8	3.9	3
30	The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
29	Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale. <i>Cancers</i> , 2021 , 13,	6.6	3
28	Molecular testing on serous effusions. <i>Diagnostic Cytopathology</i> , 2021 , 49, 640-646	1.4	3
27	Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma. <i>Gynecologic Oncology</i> , 2018 , 150, 136-142	4.9	3
26	Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 857-864	5.1	2
25	Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression. <i>Lung Cancer</i> , 2005 , 49 Suppl 1, S89-93	5.9	2
24	Recurrent fusion transcripts in squamous cell carcinomas of the vulva. <i>Oncotarget</i> , 2017 , 8, 16843-16850	3.3	2
23	MGMT promoter methylation is a rare epigenetic change in malignant effusions. <i>Cytopathology</i> , 2020 , 31, 12-15	1.3	2
22	TGF β splicing and canonical pathway activation in high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 665-678	5.1	1
21	Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 677-685	5.1	1
20	Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 473, 395-403	5.1	1

19	Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. <i>Molecular Imaging and Biology</i> , 2021 , 1	3.8	1
18	Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer. <i>Oncology Letters</i> , 2020 , 20, 2273-2279	2.6	1
17	Peptide vaccine targeting mutated : a potential novel treatment for pseudomyxoma peritonei 2021 , 9,		1
16	The Biological Role of the Long Non-coding RNA in Ovarian Carcinoma. <i>Anticancer Research</i> , 2020 , 40, 6677-6684	2.3	1
15	Molecular Cytology of Serous Effusions 2018 , 103-115		1
14	Breast Carcinoma 2012 , 69-77		1
13	Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and In Vivo Models. <i>Journal of Oncology</i> , 2020 , 2020, 1-11	4.5	1
12	The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma. <i>Cytopathology</i> , 2021 , 32, 161-168	1.3	1
11	Spatial and temporal changes in follicle distribution in the human ovarian cortex. <i>Reproductive BioMedicine Online</i> , 2021 , 42, 375-383	4	1
10	The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 489-490	5.1	0
9	Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma. <i>Apmis</i> , 2018 , 126, 309-313	3.4	0
8	Comparison of the IdyllaMSI assay with the PromegaMSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 489-490	5.1	0
7	Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma. <i>Cytopathology</i> , 2020 , 31, 572-578	1.3	0
6	Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 670185	5.7	0
5	Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 479, 419-424	5.1	0
4	Breast Carcinoma 2018 , 75-85		
3	Molecular Genetics of Uterine Sarcomas1-7		
2	Ovarian/Primary Peritoneal Carcinoma 2012 , 167-203		

- 1 Pathophysiology roles and translational opportunities of miRNAs in ovarian cancer **2022**, 317-322